Pancreatic Cancer–Associated Diabetes is Clinically Distinguishable From Conventional Diabetes

Yoon, Bo Hyung; Ang, Su Mae; Alabd, Andre; Furlong, Kevin; Yeo, Charles J.; Lavu, Harish; Winter, Jordan M.

doi:10.1016/j.jss.2020.12.015

Cited by 8 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yoon BH с соавт. по результатам обследования более 600 пациентов с ПАК среди особенностей течение диабета, в сравнении с СД2, отметили помимо более старшего возраста, более низкого индекса массы тела и уровня HbA1c, более высокий уровень аланинаминотрасферазы, более низкий уровень креатинина и большую вероятность потребности в инсулине [16]. Другие исследователи отмечают отличия в прогнозе диабета (табл.…”

Section: панкретогенный диабет и диабет ассоциированный с рпж: эпидем...unclassified

Pancreatic cancer, pancreatogenic diabetes, type 2 diabetes mellitus

Друк

2022

jour

View full text Add to dashboard Cite

Pancreatic cancer (PC) is the fourth leading cause of death among all types of cancer. PC is very aggressive with a low 5-year overall survival rate. The highest prevalence of diabetes mellitus (DM), significantly exceeding the average population, is registered among patients with prostate cancer Recommendations for systemic screening of patients with diabetes for the detection of PC are not standardized. The purpose of this review is to present an analysis of current literature data on pathogenetic relationships between DM and PC and prospects for PC screening. Research data indicate that there is a bidirectional relationship between DM and PC, in which DM can act either as a risk factor for PC or as a marker of paraneoplastic syndrome of PC. In the differential diagnosis of type 2 diabetes, pancreatogenic diabetes and diabetes associated with PC, a set of clinical signs can be used. Patients with DM who have additional signs/symptoms of increased risk can be considered as a group subject to mandatory screening. Numerous studies of various proteomic, metabolomic, genetic and transcriptomic biomarkers PC have been published. The search for an easy-to-use clinically useful and cost-effective PC marker is still ongoing.

show abstract

Section: панкретогенный диабет и диабет ассоциированный с рпж: эпидем...unclassified

Pancreatic cancer, pancreatogenic diabetes, type 2 diabetes mellitus

Друк

2022

jour

View full text Add to dashboard Cite

show abstract

“…It is a challenge to differentiate PC induced NOD from the more commonly encountered T2DM based on clinical and biochemical factors in clinical practice (Table 1 ). There are many overlaps between these two entities[ 84 - 86 ]. Munigala et al [ 87 ], identified age ≥ 65 years, heavy smoking, non-obese status at diagnosis, history of CP or gallstones as different risk factors of PC in a prospective cohort of NOD.…”

Section: Early Detection And/or Screening Models For Pc In Dmmentioning

confidence: 99%

Diabetes and pancreatic cancer: Exploring the two-way traffic

Roy¹,

Sahoo²,

Kamalanathan³

et al. 2021

WJG

View full text Add to dashboard Cite

Pancreatic cancer (PC) is often associated with a poor prognosis. Long-standing diabetes mellitus is considered as an important risk factor for its development. This risk can be modified by the use of certain antidiabetic medications. On the other hand, new-onset diabetes can signal towards an underlying PC in the elderly population. Recently, several attempts have been made to develop an effective clinical tool for PC screening using a combination of history of new-onset diabetes and several other clinical and biochemical markers. On the contrary, diabetes affects the survival after treatment for PC. We describe this intimate and complex two-way relationship of diabetes and PC in this review by exploring the underlying pathogenesis.

show abstract

“…To overcome this problem, the use of a series of filters (or sieves) using increasingly invasive (and costly) testing has been advocated [8]. There are differences in the demographic and anthropometric characteristics of patients with diabetes secondary to pancreatic cancer compared to T2DM, such as older age and lower body mass index in the former type of diabetes [44]. Statistical models have recently been developed and validated using clinically available variables (e.g., age at diabetes onset, weight change, change in fasting glucose, etc.)…”

Section: Biomarkers Of Diabetes Secondary To Pancreatic Diseasesmentioning

confidence: 99%

Distinguishing diabetes secondary to pancreatic diseases from type 2 diabetes mellitus

Hart

Andersen

Petrov

et al. 2021

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of review Diabetes secondary to pancreatic diseases (i.e., acute pancreatitis, chronic pancreatitis, and pancreatic cancer) is increasingly studied, but remains challenging to distinguish from type 2 diabetes (T2DM). We review the clinical significance and potential biomarkers that may help differentiate these types of diabetes. Recent findings Recent studies have identified several complications (including nonvascular) that occur more frequently in patients with diabetes secondary to acute and chronic pancreatitis than T2DM, and biomarkers to differentiate these types of diabetes. There have been advances that may enable the enrichment of a population of adults with new onset diabetes to potentially screen for occult pancreatic cancer, but efforts are needed to identify and validate promising diagnostic biomarkers. Summary High-quality studies are needed to more precisely understand the risk factors and natural course of diabetes secondary to pancreatic diseases. Mechanistic and interventional studies are awaited to provide insights that will distinguish diabetes secondary to pancreatic diseases and refine the management of hyperglycemia in this patient population.

show abstract

Pancreatic Cancer–Associated Diabetes is Clinically Distinguishable From Conventional Diabetes

Cited by 8 publications

References 26 publications

Pancreatic cancer, pancreatogenic diabetes, type 2 diabetes mellitus

Pancreatic cancer, pancreatogenic diabetes, type 2 diabetes mellitus

Diabetes and pancreatic cancer: Exploring the two-way traffic

Distinguishing diabetes secondary to pancreatic diseases from type 2 diabetes mellitus

Contact Info

Product

Resources

About